ESR1 and triple-negative breast carcinoma: In particular, the triple negative breast cancer, lacking of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), is resistant to therapies, and is associated with reduced survival for tumor recurrence and metastasis [26].